Medicamen Biotech Limited (NSE:MEDICAMEQ)

Market Cap	4.39B +7.3%
Revenue (ttm)	2.06B +22.2%
Net Income	96.07M +21.5%
EPS	7.45 +12.2%
Shares Out	n/a
PE Ratio	45.73
Forward PE	n/a
Dividend	1.00 (0.32%)
Ex-Dividend Date	Sep 18, 2026

Volume	9,526
Open	320.00
Previous Close	319.95
Day's Range	310.35 - 326.75
52-Week Range	212.40 - 447.65
Beta	0.73
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Medicamen Biotech

Medicamen Biotech Limited, a pharmaceutical company, research, develops, manufactures, markets, and sells pharmaceutical formulations in India and internationally. The company provides tablets, capsules, dry syrups, oral liquids, ointments, and other pharmaceutical dosage forms. Its products are used in therapeutic areas comprising cancer care, cardiology, CNS, diabetology, anti-infective, anti-malarials, vitamins and supplements, antibiotics, pain management, and other generics. Medicamen Biotech Limited was incorporated in 1993 and is based i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 405
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: MEDICAMEQ

Financial Performance

In fiscal year 2026, Medicamen Biotech's revenue was 1.98 billion, an increase of 18.04% compared to the previous year's 1.68 billion. Earnings were 96.41 million, an increase of 35.64%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 24, 2026

Data Sources Report a data error